NASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis $56.00 +0.02 (+0.04%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Belite Bio Stock (NASDAQ:BLTE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Belite Bio alerts:Sign Up Key Stats Today's Range$55.80▼$56.1050-Day Range$46.47▼$56.0052-Week Range$30.21▼$56.50Volume11,502 shsAverage Volume49,192 shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$59.00Consensus RatingBuy Company OverviewBelite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Read More… Don’t Miss Out! Get 2 Hot AI Stocks for Under $10/Share 🚀 (Ad)Artificial Intelligence (AI) stocks are booming, and now is your chance to get in on the action — without breaking the bank! We’ve just uncovered 2 must-buy AI stocks trading for under $10/share, and they’re showing serious potential for growth.Click here to get your FREE report delivered instantly! Belite Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks20th Percentile Overall ScoreBLTE MarketRank™: Belite Bio scored higher than 20% of companies evaluated by MarketBeat, and ranked 925th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBelite Bio has only been the subject of 2 research reports in the past 90 days.Read more about Belite Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($1.19) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -45.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -45.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 17.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.92% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Belite Bio has recently decreased by 2.46%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.92% of the outstanding shares of Belite Bio have been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Belite Bio has recently decreased by 2.46%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News SentimentN/A News SentimentBelite Bio has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Belite Bio this week, compared to 2 articles on an average week.Search Interest6 people have searched for BLTE on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows4 people have added Belite Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLTE Stock News HeadlinesBelite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual MeetingOctober 15 at 12:13 PM | markets.businessinsider.comBelite Bio (NASDAQ:BLTE) Sets New 12-Month High - Still a Buy?October 9, 2024 | americanbankingnews.com$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…October 17, 2024 | WealthPress (Ad)Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual SummitOctober 8, 2024 | finance.yahoo.comBelite Bio (NASDAQ:BLTE) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comBelite Bio (NASDAQ:BLTE) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comCassava settles SEC charges related to Alzheimer’s candidate for $40MSeptember 28, 2024 | seekingalpha.comHere's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn SituationSeptember 24, 2024 | finance.yahoo.comSee More Headlines BLTE Stock Analysis - Frequently Asked Questions How have BLTE shares performed this year? Belite Bio's stock was trading at $45.75 at the start of the year. Since then, BLTE shares have increased by 22.4% and is now trading at $56.00. View the best growth stocks for 2024 here. How were Belite Bio's earnings last quarter? Belite Bio, Inc (NASDAQ:BLTE) released its quarterly earnings data on Friday, August, 9th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.03. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share. Who are Belite Bio's major shareholders? Belite Bio's top institutional investors include GAMMA Investing LLC. How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Belite Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Grayscale Ethereum Trust (ETH) (ETHE), Marathon Oil (MRO) and Vale (VALE). Company Calendar Last Earnings8/09/2024Today10/17/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLTE CUSIPN/A CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$59.00 High Stock Price Target$60.00 Low Stock Price Target$57.00 Potential Upside/Downside+5.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.84% Return on Assets-37.97% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book17.07Miscellaneous Outstanding Shares29,794,000Free Float26,544,000Market Cap$1.67 billion OptionableNot Optionable Beta-1.50 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:BLTE) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.